Karyopharm Therapeutics Inc. (KPTI) Social Stream



Karyopharm Therapeutics Inc. (KPTI): $8.32

-0.05 (-0.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Featured Post From StockTwits About KPTI

$KPTI Estimated S.I as on July 28th is 25.78%

Not all the Shorts with S.I squeeze, the price moment, average days the shorts on loan , average price the stock was shorted plays significant roles – I update the spread sheet based on every day stock moment and estimate how much loss the shorts are in every day.
This will help to understand the likely short squeeze, higher the losses the Shorts are in – more likely the squeeze would happen, not just the S.I %age itself.

I was more than $4400 last week with 15K investment – just by shorting the stocks and investing in high S.I stock. I traded only 3 stocks last week, the criteria I discovered was very successful. My patreon members were also part of the success story.

Please join my Patreon channel for access to this sheet in full and my day trade alerts. You can obviously quit any time if don’t like the content there is no upfront cost.

https://www.patreon.com/ShortedStocks?fan_landing=true
MrShort, published July 29, 2021

What Else are KPTI Traders Talking About?


Other tickers frequently mentioned alongside KPTI are KDMN and GTHX.

Other Notable StockTweets About KPTI


$KDMN, pegged at $500m annual peak sales and significant improvement in quality of life for chronic GVHD patients (meaning payers will provide coverage).

"Patients receiving [belumosudil] reported significant improvements in chronic GVHD symptoms, showing that not only did treatment result in organ responses, but it also made people feel better. This is so important for a chronic disease with a high symptom burden," Stephanie Lee, MD, MPH, professor at the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, and research director of the Long-Term Follow-Up Program at Fred Hutchinson, noted in the release.

https://www.targetedonc.com/view/fda-approves-belumosudil-for-chronic-graft-versus-host-disease

$MRTX $GTHX $KPTI

Jasooon, published July 17, 2021

$KPTI Why stop a Phase 1 trial? Probably because Richard Paulson rightly decided he can't throw money at everything under the sun like his predecessor who didn't seem to have a sense of what constitutes shareholder value, and you can't rely on shareholders indefinitely as ATM machines and burn through cash like wildfire. The new owner of Karyopharm will have a lot more money to pursue these things.

celebratelife, published July 9, 2021

$KPTI YEET YEET!! Glad I bought in the $8 range and never looked back!

New CEO is decent. Well that was a steal the huge short float might of helped. let's see where this opens tmmrw because I see a breakout to the $11-12 range coming !

YEET

Texas1977, published July 1, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5753 seconds.